Cargando…
The module triad: a novel network biology approach to utilize patients’ multi-omics data for target discovery in ulcerative colitis
Tumor necrosis factor-[Formula: see text] inhibitors (TNFi) have been a standard treatment in ulcerative colitis (UC) for nearly 20 years. However, insufficient response rate to TNFi therapies along with concerns around their immunogenicity and inconvenience of drug delivery through injections calls...
Autores principales: | Voitalov, Ivan, Zhang, Lixia, Kilpatrick, Casey, Withers, Johanna B., Saleh, Alif, Akmaev, Viatcheslav R., Ghiassian, Susan Dina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755270/ https://www.ncbi.nlm.nih.gov/pubmed/36522454 http://dx.doi.org/10.1038/s41598-022-26276-x |
Ejemplares similares
-
A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study
por: Wang, Mengran, et al.
Publicado: (2021) -
Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
por: Cohen, Stanley, et al.
Publicado: (2022) -
A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
por: Cohen, Stanley, et al.
Publicado: (2021) -
A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
por: Cohen, Stanley, et al.
Publicado: (2021) -
A Unique Triad: Ulcerative Colitis, Primary Sclerosing Cholangitis, and Autoimmune Hemolytic Anemia
por: Naqvi, Syeda, et al.
Publicado: (2018)